BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 12111443)

  • 1. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
    Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
    Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
    Kennedy JS; Polinsky RJ; Johnson B; Loosen P; Enz A; Laplanche R; Schmidt D; Mancione LC; Parris WC; Ebert MH
    J Clin Psychopharmacol; 1999 Dec; 19(6):513-21. PubMed ID: 10587286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
    Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
    Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
    Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
    Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
    Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
    Gobburu JV; Tammara V; Lesko L; Jhee SS; Sramek JJ; Cutler NR; Yuan R
    J Clin Pharmacol; 2001 Oct; 41(10):1082-90. PubMed ID: 11583476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
    Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
    Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The recovery of cerebrospinal fluid acetylcholinesterase activity in Alzheimer's disease patients after treatment with metrifonate.
    Unni L; Vicari S; Moriearty P; Schaefer F; Becker R
    Methods Find Exp Clin Pharmacol; 2000; 22(1):57-61. PubMed ID: 10791297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
    Almkvist O; Darreh-Shori T; Stefanova E; Spiegel R; Nordberg A
    Eur J Neurol; 2004 Apr; 11(4):253-61. PubMed ID: 15061827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
    Cutler NR; Polinsky RJ; Sramek JJ; Enz A; Jhee SS; Mancione L; Hourani J; Zolnouni P
    Acta Neurol Scand; 1998 Apr; 97(4):244-50. PubMed ID: 9576639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
    Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
    J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
    Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
    Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.